Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases

Pancreatic Diseases Clinical Trial

Official title:

Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT02471170
• Other study ID #: UPCC 02215
• Status: Enrolling by invitation
• Start date: September 10, 2015
• Est. completion date: January 1, 2025

Study information

• Verified date: October 2023
• Source: Abramson Cancer Center at Penn Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to collect blood samples to detect potential markers of pancreatic cancer in the blood and link these findings to medical and health information. Information from this study may help to provide insight into the detection of pancreas cancer in the blood before it can be found by other methods or provide a method of monitoring the status of pancreatic cancer throughout a treatment course. Another purpose of this study is to collect blood to create a biobank.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 100
• Est. completion date: January 1, 2025
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The subject must be a patient at the Hospital of the University of Pennsylvania

• The subject must be under evaluation and/or treatment for a pancreatic disease
• The subject must be under evaluation and/or treatment for a non-pancreatic disease. For example, patients undergoing routine colonoscopy within the clinical practice will be asked to consent to provide control samples.

2. The subject must be able to provide informed consent or have an acceptable surrogate capable of giving consent on the subject's behalf

3. The subject must be 18 years of age or older

Exclusion Criteria:

1. The subject or acceptable surrogate does not provide informed consent

2. Subject is a prisoner

3. Subject is under 18 years of age

Related Conditions & MeSH terms

• Pancreatic Diseases

Locations

Country	Name	City	State
United States	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Abramson Cancer Center at Penn Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Collection of blood and tissue samples from subjects with pancreatic diseases		3 years